Formulary Watch |

Formulary Watch covers formularies, pharmacy benefit management companies, drug approvals, and other matters related to medications, their prices and insurance coverage.

Editorial Contact: Denise Myshko: dmyshko@mjhlifesciences.com

All News

 Stepan Popov-stock.adobe.com
Updated: FDA Committee, Concerned about Bias, Votes No on Psychedelic in PTSD
Updated: FDA Committee, Concerned about Bias, Votes No on Psychedelic in PTSD
June 5, 2024
Patients with PTSD in the clinical trials of midomafetamine were able to guess whether they received treatment or placebo. Regulators and advisory committee members said this could have impacted efficacy results. FDA’s decision is expected by Aug. 11, 2024.
LucyRx Partners with Employers for a New Kind of PBM
LucyRx Partners with Employers for a New Kind of PBM
LucyRx Partners with Employers for a New Kind of PBM
May 31, 2024
LucyRx will begin providing pharmacy benefit services to self-insured employers, covering about half a million lives, beginning in January 2025.
FDA Approves Non-Stimulant ADHD Medication
FDA Approves Non-Stimulant ADHD Medication
FDA Approves Non-Stimulant ADHD Medication
May 30, 2024
Onyda XR is a liquid form of clonidine that can be used as monotherapy or as adjunctive therapy for patients 6 years of age and older with ADHD.
 WrightStudio-stock.adobe.com
Global Spending on Cancer Drugs to Increase to $409 Billion
Global Spending on Cancer Drugs to Increase to $409 Billion
May 28, 2024
In the United States, spending on oncology therapies rose to $99 billion in 2023, and is expected to grow to nearly $180 billion in 2028, finds a recent report by IQVIA Institute for Human Data Science.
 Ольга Тернавская-stock.adobe.com
Updated: FDA Approves First Interchangeable Biosimilars to Eylea
Updated: FDA Approves First Interchangeable Biosimilars to Eylea
May 21, 2024
Yesafili and Opuviz are approved to treat patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.
Optum Rx to Offer Guarantee-Based Pricing Model
Optum Rx to Offer Guarantee-Based Pricing Model
Optum Rx to Offer Guarantee-Based Pricing Model
May 20, 2024
The new program will launch in January 2025 and provide plan sponsors greater predictability of pharmacy spend.
MilletStudio-stock.adobe.com
FDA Sets Review Date for Gene Therapy for Enzyme Deficiency
FDA Sets Review Date for Gene Therapy for Enzyme Deficiency
May 14, 2024
Upstaza is a one-time gene therapy to treat patients 18 months and older with AADC deficiency. It has a review date of Nov. 13, 2024.
K KStock-stock.adobe.com
KFF: 1 in 8 Adults have Used GLP-1 Agonists
KFF: 1 in 8 Adults have Used GLP-1 Agonists
May 10, 2024
New KFF poll finds most of the adults who have taken GLP-1 therapies have diabetes or heart disease. But 38% said they have used for these drugs solely to lose weight.
 lexiconimages-stock-adobe.com
Orladeyo Can Reduce Health Resource Use in HAE
Orladeyo Can Reduce Health Resource Use in HAE
May 9, 2024
An analysis of claims data shown Orladeyo can reduce hospitals and emergency room visit of patients with the rare genetic condition hereditary angioedema.
freshidea-stock.adobe.com
Investigational Anticoagulant May be Cost-Effective
Investigational Anticoagulant May be Cost-Effective
May 8, 2024
If approved, abelacimab could yield cost savings in preventing stroke in patients with atrial fibrillation due to its ability to prevent bleeding.
© 2024 MJH Life Sciences

All rights reserved.